Acetylome Interpretation: Site-Level vs Protein-Level Change (and What You Can Claim)

If you work with an acetylome dataset long enough, you’ll see the same reviewer questions land again and again—because they’re reasonable. In enrichment-based PTM workflows, it’s easy to confuse a measured signal with regulation. What looks like a strong site-level change may be driven by protein abundance shifts, ambiguous site localization, or missingness and batch effects.

This article is a reviewer-ready interpretation playbook. It focuses on what to check, what to report, and how far your conclusions can safely go—without rehashing acetylation biology or methods.

Key Takeaways

• Decide upfront what your unit of change is: protein-level, site-level, or pathway-level—each supports a different claim.
• Treat protein abundance confounding as the default null explanation until you rule it out with explicit checks and transparent reporting.
• A “significant site” is not automatically a “regulated lysine”: localization confidence gates what you can claim.
• Effect size + BH-FDR are necessary but not sufficient; missingness and batch structure can still flip your story.
• Reviewer trust is earned by minimum tables/figures and clear language about what is consistent with regulation vs what proves mechanism.

Why acetylome interpretation is harder than it looks

Acetylome studies are unusually vulnerable to over-interpretation for a simple reason: the data you analyze is already the product of selection. Enrichment, peptide detectability, and MS/MS sampling all shape which modified peptides you ever see—before statistics enter the picture.

That doesn’t mean acetylome results are unreliable. It means your conclusions must be conditional and explicit:

• Conditional on protein context (is the modified signal independent of protein change?).
• Conditional on site validity (is the modification localized to that lysine with high confidence?).
• Conditional on transparent thresholds and QC (can a reviewer reconstruct why a site made it into your claims?).

The goal here is not to make claims smaller. It’s to make them defensible.

Define the unit of change: protein-level, site-level, or pathway-level?

Before you interpret any volcano plot, define what “changed” actually means in your manuscript. This sounds semantic, but it’s the difference between a clean rebuttal and an endless back-and-forth.

Three endpoints, three different claims

Protein-level change answers: Is the protein more or less abundant across conditions? This supports claims about expression/abundance shifts (still not necessarily mechanism).

Site-level acetylation change answers: Is the modification signal at a specific lysine changing beyond what you’d expect from protein abundance? This supports claims about site-associated regulation—if localization and confounding checks pass.

Pathway-level change answers: Do many proteins/sites in a pathway show coordinated shifts? This supports statements about pathway association, enrichment, or affected biological programs—usually with softer causality language.

A reviewer will often accept a pathway-level association even when individual sites are borderline—if you report the uncertainty honestly.

What to decide before you interpret anything

Decide (and write down in Methods or Supplement) the following before you look for narratives:

1. Your contrasts: which group comparisons are primary vs exploratory.
2. Your significance rule: BH-FDR threshold, and whether you require a minimum effect size.
3. Your effect size unit: typically log2 fold-change at the site level.
4. Your localization gate: a threshold for site probability/score, and how you handle ambiguous sites.
5. Your missingness rule: what counts as “quantifiable,” and what gets filtered.
6. Your batch/QC rule: what constitutes a batch effect signal strong enough to reprocess.

These decisions don’t just help the reader—they protect you from moving goalposts under pressure.

The core problem: protein abundance confounding (how to detect it)

When reviewers ask, “Is this differential acetylation just protein upregulation?”, they are pointing to the most common failure mode in PTM enrichment datasets: the modified-peptide signal can move because the protein moved.

A practical way to think about this: a site-level acetylation signal is a composite of (i) how much protein is present, (ii) how much of it carries the modification (occupancy/stoichiometry), and (iii) how well you measured that peptide in your run.

Methods literature has explicitly shown that protein-level adjustment can be required to control false discoveries in differential PTM analysis; see the MCP paper on MSstatsPTM: Statistical Relative Quantification of Posttranslational Modifications.

What confounding looks like in real data

In real acetylome projects (often a dozen-ish samples per group), confounding rarely announces itself as an obvious mistake. It shows up as patterns you can spot if you know what to look for:

• “Everything on this protein moves together.” Multiple acetylation sites on the same protein shift in the same direction with similar magnitudes.
• Site changes track protein changes. The modified site’s fold-change is similar to the protein’s fold-change, and the direction matches.
• Large effects concentrated in high-abundance proteins. This can be a real biology signal, but it can also reflect measurement bias (high-abundance proteins are easier to quantify and less missing).
• A single sample or batch drives the effect. Remove or correct for that structure, and the site no longer passes thresholds.

None of these patterns “prove” confounding. But they should stop you from writing a strong site-regulation claim without more context.

Checks that keep claims honest

A reviewer-ready confounding check doesn’t require exotic modeling. It requires that you show the relationship between site-level change and protein-level change, and you disclose how you handled it.

At minimum, you want to be able to answer these questions in one paragraph:

1. Did you quantify protein abundance in the same samples? If yes, how was it derived (unmodified peptides, global proteome channel, etc.)?
2. Did you adjust site-level inference for protein abundance? If yes, state the approach conceptually (e.g., protein-adjusted site analysis) and report thresholds.
3. Did you flag sites where protein changes could explain the signal? If yes, state the rule.

If you can’t do protein adjustment, you can still protect your claims by adding a “protein context note” to your key site table:

• “Site change direction matches protein change; interpret as abundance-associated.”
• “Site change exceeds protein change magnitude; consistent with additional site-level regulation.”
• “Protein not confidently quantified; site-level claim is limited.”

This is also where reporting transparency matters. A site list without protein context invites the reviewer to assume confounding.

How to phrase conclusions responsibly

Once you’ve done the checks, your wording should track the evidence.

Use language like:

• “The observed site-level acetylation change is consistent with regulation beyond protein abundance.”
• “Site-level acetylation is associated with condition X after accounting for protein abundance.”
• “These data support a model in which acetylation at K### may be modulated under condition Y (subject to localization confidence).”

Avoid language that implies mechanism you did not test:

• “Acetylation at this site drives phenotype.”
• “This lysine is regulated by enzyme Z” (unless you have enzyme perturbation evidence).
• “This proves acetylation-dependent activation.”

A good rule: if your analysis is observational, your verbs should be observational.

Normalization choices that change your story

Normalization is not a technical footnote in acetylome work—it’s an interpretive decision. Different normalization choices can turn the same dataset into:

• a protein abundance story,
• a site occupancy story,
• or a hybrid that is hard to defend.

This section stays principle-based (no tool names), because reviewers care about what you normalized to and why.

If you want to be explicit about what kind of study this is, you can describe it as lysine acetylation proteomics with enrichment-based quantification—then immediately pivot back to interpretation (not methods).

What to normalize to (and what not to)

The question is: what do you consider the baseline that should be equal across samples?

Common baselines include:

1. Sample loading / total peptide amount (basic comparability): helps when technical loading differs.
2. Global signal distribution (bringing samples to similar intensity distributions): can stabilize variance, but can also mask global biological shifts.
3. Protein abundance context (site signal interpreted relative to protein quantity): better aligned with site-level claims when protein changes are present.

What to be careful about:

• Normalizing away true global shifts. If a condition plausibly causes a broad acetylation shift, aggressive global normalization can compress it.
• Pretending normalization solved confounding. Normalization reduces technical variation; it doesn’t automatically separate site occupancy from protein abundance.

If your core claim is site-level regulation, your reporting should show that your normalization and modeling support that claim—not just that a p-value passed.

Multi-group comparisons: predefine contrasts

If you have more than two groups (time courses, dose, genotype × treatment), the most common reviewer objection is not statistical power—it’s interpretive flexibility.

Be explicit about:

• which comparisons are primary,
• whether you tested interaction effects,
• and whether exploratory contrasts are labeled as exploratory.

A clean practice is to define contrasts in advance and then present results in that same structure. It prevents “we tried several comparisons and reported the one that worked” suspicion.

Red flags

Reviewers are trained to detect a few patterns that correlate strongly with over-claiming:

• Thresholds only appear after a reviewer asks.
• Effect size isn’t reported, only adjusted p-values.
• Sites are filtered, but reasons aren’t logged.
• The narrative depends on re-running analysis with new cutoffs until the plot looks right.

If you want your conclusions to be trusted, make the analysis legible.

Localization confidence: when a “site” is not a site

In acetylome papers, “KXXX is acetylated” is often treated as a fact. But site-level claims only hold if the spectra support that lysine over plausible alternatives.

This is not pedantry. It directly changes what you can claim:

• High confidence localization supports a site-specific statement.
• Ambiguous localization supports, at most, a peptide-level or region-level statement.

General PTM localization frameworks emphasize that identification confidence and site localization confidence are not the same object; see PTMProphet and the broader review on modification site localization scoring strategies and performance.

What localization fields should be reported

To make site-level claims reviewer-ready, report localization in a way that allows a reader to see ambiguity, not just a binary “localized” label.

Minimum fields to include (for each reported site):

• A site localization probability/score (method-specific, but must be explicit).
• A runner-up localization metric (or delta score) when available.
• The rule for handling multi-site peptides (multiple lysines on one peptide).
• Whether localization confidence was controlled via a false localization concept (when applicable).

You can cite classic probability framing for localization (e.g., the AScore concept) and generalized implementations that apply beyond phosphorylation (e.g., pyAscore).

How localization affects what you can claim

A clean approach is to tie localization confidence directly to claim strength:

• High localization confidence → “acetylation at K### increases/decreases” (site-level claim).
• Moderate / ambiguous localization → “the acetylated peptide spanning residues X–Y changes” (peptide-level claim).
• Low localization confidence → do not use the site for mechanistic interpretation; keep it in supplementary tables with flags.

This reduces reviewer friction because you are preemptively drawing the boundary.

Missing values and batch effects: interpretation traps

If protein abundance confounding is the most common conceptual error, missingness and batch effects are the most common practical error.

Two datasets can have the same number of identified sites and the same nominal BH-FDR threshold, but radically different interpretability depending on how missingness is distributed.

Missingness patterns you must summarise

Missing values are not random in proteomics. Many are intensity-dependent (left-censored) or structure-dependent (batch/run-order effects). A useful starting point is to treat missingness as a measurable feature of your dataset, not an inconvenience.

A classic discussion of this problem in label-free quantitative proteomics is “Accounting for the Multiple Natures of Missing Values in Label-Free Quantitative Proteomics Data” (J. Proteome Research).

Reviewer-ready summaries include:

• per-group missingness rates,
• sites missing in one group but present in another,
• whether missingness correlates with intensity,
• and how many sites pass your “quantifiable” rule.

If you use imputation, you should acknowledge that it can change effect sizes and false positives. Papers evaluating imputation choices using downstream criteria (not just reconstruction error) are a good way to frame this; for example, see “Evaluating Proteomics Imputation Methods with Improved Criteria” (PMC).

Batch checks you should show

Batch effects don’t need to be dramatic to cause over-claiming. In acetylome data, batch structure can masquerade as biology because enrichment and MS sampling amplify differences.

Minimum checks to show (even as supplementary “QC one-pager”):

• PCA (or similar) colored by batch/run order and by biological group.
• Replicate correlations within and across batches.
• Evidence that the strongest differential sites are not simply batch-separating features.

A practical framework for QC expectations in quantitative proteomics is described in “A framework for quality control in quantitative proteomics” (PMC). Use it to justify why you reported the QC you did.

Rework triggers

You should pause interpretation and consider reprocessing if you see:

• group separation that disappears when coloring by batch,
• a small number of runs driving most “significant” sites,
• extreme missingness asymmetry across groups,
• or threshold sensitivity where small parameter changes flip top conclusions.

These are not failures—they’re signals to tighten the analysis before you attach biology to noise.

Reviewer-ready reporting: the minimum tables and figures

Reviewers don’t reject acetylome papers because they dislike acetylation. They reject them because the chain of evidence from raw signal → filtered site list → claim is not transparent.

Community reporting expectations in proteomics emphasize reproducibility and minimum metadata disclosure; see the MIAPE primer (PubMed) and the HUPO-PSI standardization report “Ten Years of Standardizing Proteomic Data” (PMC).

Here is a practical “minimum package” that reduces reviewer back-and-forth.

Minimum site-level table (fields that prevent over-claiming)

Your “significant site list” should be more than a list of IDs. Include fields that encode interpretation boundaries.

Minimum recommended columns:

• Site ID (protein accession + residue position + modified residue)
• Effect size (e.g., log2 fold-change)
• BH-FDR (q-value)
• Localization confidence (probability/score + ambiguity flag)
• Protein context note (whether protein abundance change could explain signal; how assessed)
• Missingness flag (e.g., group-specific missingness / imputation applied / filtered)
• Batch flag (site correlated with batch/run order; yes/no and rule)
• Filter reason (if removed from “interpretable” list)

Here’s an optional schematic of that table structure:

Minimum figures (what reviewers expect to see)

Think of figures as proof that your thresholds and QC were applied consistently.

A reviewer-friendly set includes:

1. QC one-pager: sample counts, missingness overview, batch summary, replicate correlation.
2. Main contrast visualization: volcano/MA plot annotated with key sites (and showing effect size + BH-FDR gates).
3. Batch check visualization: PCA colored by batch and group, or run-order trend plots.
4. Missingness visualization: heatmap or bar summary by group, highlighting MNAR patterns.

If you include these, a reviewer can disagree with your interpretation—but they can’t reasonably claim you hid the decision process.

Consultation-only closing

If you’re not sure what you can responsibly claim (and what you should phrase as “associated with”), send us your study goal, sample type/size, group design, and the kind of claim you want the data to support. Our scientists can recommend a reviewer-ready interpretation plan and reporting structure for your acetylome project.

For project scoping, see PTMs proteomics services (including acetylome proteomics services) and the PTM proteomics resource library for related technical reading.

For research use only. Not for clinical diagnosis, treatment, or individual health assessments.

Author

CAIMEI LI — Senior Scientist at Creative Proteomics
LinkedIn: CAIMEI LI